ARTICLE | Company News
Teva and H. Lundbeck extend deal
February 15, 2001 8:00 AM UTC
TEVA and H. Lundbeck (CSE:LUN) extended their 1999 development and marketing deal to include an oral preparation of Copaxone copolymer-1, a synthetic polypeptide in Phase III trials to treat multiple ...